Related Experiment Video
Updated: Jun 24, 2025
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers
Jose Mario Bello Pineda1,2,3,4, Robert K Bradley1,2,3
1Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, United States.
Abstract:
Cancer immune evasion contributes to checkpoint immunotherapy failure in many patients with metastatic cancers. The embryonic transcription factor DUX4 was recently characterized as a suppressor of interferon-γ signaling and antigen presentation that is aberrantly expressed in a small subset of primary tumors. Here, we report that DUX4 expression is a common feature of metastatic tumors, with ~10-50% of advanced bladder, breast, kidney, prostate, and skin cancers expressing DUX4. DUX4 expression is significantly associated with immune cell exclusion and decreased objective response to PD-L1 blockade in a large cohort of urothelial carcinoma patients. DUX4 expression is a significant predictor of survival even after accounting for tumor mutational burden and other molecular and clinical features in this cohort, with DUX4 expression associated with a median reduction in survival of over 1 year. Our data motivate future attempts to develop DUX4 as a biomarker and therapeutic target for checkpoint immunotherapy resistance.
Insights
The embryonic transcription factor DUX4 is commonly found in metastatic cancers, hindering immune responses and reducing immunotherapy effectiveness. Targeting DUX4 could improve treatments for patients with advanced cancers resistant to current therapies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer immune evasion is a key reason for immunotherapy failure in metastatic cancers.
- The embryonic transcription factor DUX4 suppresses interferon-γ signaling and antigen presentation.
- Aberrant DUX4 expression is observed in a subset of primary tumors.
Purpose of the Study:
- To investigate the prevalence of DUX4 expression in metastatic cancers.
- To determine the association of DUX4 expression with immune cell exclusion and immunotherapy response.
- To evaluate DUX4 as a prognostic biomarker for patient survival.
Main Methods:
- Analysis of DUX4 expression in various metastatic cancer types.
- Correlation of DUX4 expression with immune cell infiltration in tumors.
- Assessment of response to PD-L1 blockade in urothelial carcinoma patients.
- Survival analysis considering tumor mutational burden and clinical factors.
Main Results:
- DUX4 expression is prevalent in ~10-50% of advanced bladder, breast, kidney, prostate, and skin cancers.
- DUX4 expression correlates with immune cell exclusion and reduced response to PD-L1 blockade.
- DUX4 is a significant predictor of survival, associated with over a year reduction in median survival.
Conclusions:
- DUX4 expression is a common characteristic of metastatic tumors and is linked to immunotherapy resistance.
- DUX4 may serve as a predictive biomarker for checkpoint immunotherapy response.
- DUX4 presents a potential therapeutic target for overcoming immunotherapy resistance in cancer.
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...